0001209191-21-036120.txt : 20210526 0001209191-21-036120.hdr.sgml : 20210526 20210526210454 ACCESSION NUMBER: 0001209191-21-036120 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210526 FILED AS OF DATE: 20210526 DATE AS OF CHANGE: 20210526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Josey John A. CENTRAL INDEX KEY: 0001776351 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 21968221 MAIL ADDRESS: STREET 1: C/O PELOTON THERAPEUTICS, INC. STREET 2: 2330 INWOOD ROAD, SUITE 226 CITY: DALLAS STATE: TX ZIP: 75235 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 206-913-4300 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-05-26 0 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001776351 Josey John A. 395 OYSTER POINT BLVD, SUITE 217 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 65292 D Stock Option (right to buy Common Stock) 16.00 2031-05-22 Common Stock 1181 D Stock Option (right to buy Common Stock) 16.00 2031-05-22 Common Stock 63000 D Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met. The option vests as to 1/48th of the total shares on each monthly anniversary, beginning on November 6, 2020, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Charles N. York II, as Attorney-in-Fact 2021-05-26 EX-24.3_988524 2 poa.txt POA DOCUMENT LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jeremy Bender and Charles N. York II, and each of them, a true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of Day One Biopharmaceuticals, Inc. (the "Company"), any and all Form 3, 4 or 5 reports required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and the rules thereunder with respect to transactions in securities of the Company; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 report and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in her/his discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or her/his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 12, 2021. /s/ John A. Josey